Imig J D, Navar L G, Roman R J, Reddy K K, Falck J R
Department of Physiology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
J Am Soc Nephrol. 1996 Nov;7(11):2364-70. doi: 10.1681/ASN.V7112364.
Epoxygenase metabolites of arachidonic acid are produced by the kidney and have been implicated in the control of renal blood flow. This study examined the preglomerular actions of various epoxyeicosatrienoic acids (EET). By use of the in vitro blood-perfused juxtamedullary nephron preparation, interlobular and afferent arteriolar diameter responses to 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET were determined. Diameters of interlobular and afferent arterioles preconstricted with 0.5 microM norepinephrine averaged 24 +/- 1 microns (N = 27) and 17 +/- 1 microns (N = 32), respectively, at a renal perfusion pressure of 100 mm Hg. Superfusion with 0.01 to 100 nM 11,12-EET caused graded increases in diameters of the interlobular and afferent arterioles. At a dose of 100 nM, 11,12-EET increased the diameters of the interlobular and afferent arterioles by 18 +/- 2% (N = 10) and 20 +/- 3% (N = 9), respectively. The vasodilatory response to 11,12-EET was stereoselective because 11,12(R,S)-EET but not 11,12(S,R)-EET increased the diameters of the interlobular and afferent arterioles. 14,15-EET had a much smaller effect and increased the diameters of the these vessels by 10%; 8,9-EET did not significantly affect vascular diameters. In contrast, 5,6-EET constricted the interlobular and afferent arterioles by 16 +/- 3% (N = 6) and 21 +/- 3% (N = 7), respectively. The corresponding diols, 5,6-DIHETE and 11,12-DIHETE, had no effect on diameters of the interlobular and afferent arterioles at concentrations up to 1 microM. The vasodilatory response to 11,12-EET was not affected by removal of the endothelium or by inhibition of cyclooxygenase with indomethacin. In contrast, the vasoconstrictor response to 5,6-EET was abolished by both removal of the endothelium or cyclooxygenase inhibition. The thromboxane/ enderoperoxide receptor inhibitor, SQ 29,548, resulted in a 60% attenuation of the afferent arteriolar vasconstriction to 5,6-EET. These results indicate that the preglomerular vasoconstriction to 5,6-EET is cyclooxygenase dependent and requires an intact endothelium, whereas the vasodilation to 11,12-EET is stereoselective and is the result of direct action of the epoxide on the preglomerular vascular smooth muscle.
花生四烯酸的环氧合酶代谢产物由肾脏产生,并与肾血流量的调控有关。本研究检测了各种环氧二十碳三烯酸(EET)对肾小体前的作用。通过使用体外血液灌注的近髓肾单位制备方法,测定了小叶间动脉和入球小动脉对5,6-EET、8,9-EET、11,12-EET和14,15-EET的直径反应。在肾灌注压为100 mmHg时,用0.5 microM去甲肾上腺素预收缩的小叶间动脉和入球小动脉的直径分别平均为24±1微米(N = 27)和17±1微米(N = 32)。用0.01至100 nM的11,12-EET进行灌流,可使小叶间动脉和入球小动脉的直径逐渐增加。在100 nM的剂量下,11,12-EET可使小叶间动脉和入球小动脉的直径分别增加18±2%(N = 10)和20±3%(N = 9)。对11,12-EET的血管舒张反应具有立体选择性,因为11,12(R,S)-EET而非11,12(S,R)-EET可增加小叶间动脉和入球小动脉的直径。14,15-EET的作用要小得多,可使这些血管的直径增加10%;8,9-EET对血管直径没有显著影响。相反,5,6-EET可使小叶间动脉和入球小动脉分别收缩16±3%(N = 6)和21±3%(N = 7)。相应的二醇,5,6-DIHETE和11,12-DIHETE,在浓度高达1 microM时对小叶间动脉和入球小动脉的直径没有影响。对11,12-EET的血管舒张反应不受内皮去除或用吲哚美辛抑制环氧化酶的影响。相反,对5,6-EET的血管收缩反应可因内皮去除或环氧化酶抑制而消除。血栓素/内过氧化物受体抑制剂SQ 29,548可使入球小动脉对5,6-EET的血管收缩作用减弱60%。这些结果表明,对5,6-EET的肾小体前血管收缩是环氧化酶依赖性的,且需要完整的内皮,而对11,12-EET的血管舒张是立体选择性的,是环氧化物对肾小体前血管平滑肌直接作用的结果。